Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas

ConclusionsOur data indicate that CD79b could be used as a target for CAR T-cell therapy of B-cell lymphomas, and further clinical development is warranted.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research